Related Experiment Videos
Nitric oxide (NO) in the cardiovascular system: role in atherosclerosis and hypercholesterolemia
1Division of Clinical Physiology, Göteborg University, Sweden.
Insights
Atherosclerosis involves vascular changes and impaired blood flow, often complicated by thrombosis. Endothelial dysfunction, specifically reduced nitric oxide (NO) formation, is a key functional defect that can be reversed with lipid-lowering treatments.
Area of Science:
- Cardiovascular Medicine
- Vascular Biology
- Pathophysiology
Background:
- Atherosclerosis is a progressive vascular disease marked by media hypertrophy, intimal thickening, and plaque formation, leading to impaired tissue perfusion.
- Advanced atherosclerosis can involve thrombosis and is increasingly recognized as a functional disorder.
- Endothelial dysfunction, a hallmark of atherosclerosis and hypercholesterolemia, impairs normal vasodilation and platelet regulation.
Purpose of the Study:
- To elucidate the functional aspects of atherosclerosis, focusing on endothelial dysfunction and its underlying mechanisms.
- To investigate the role of nitric oxide (NO) in the pathophysiology of atherosclerosis.
- To assess the impact of endothelial dysfunction on coronary vasodilation in ischemic heart disease and the potential for therapeutic reversal.
Main Methods:
- Review of current research on the structural and functional changes in atherosclerosis.
- Analysis of the role of endothelial dysfunction in impaired vasodilation and platelet activity.
- Examination of nitric oxide (NO) formation and its protective effects against atherosclerotic changes.
Main Results:
- Endothelial dysfunction in atherosclerosis is characterized by impaired nitric oxide (NO) production, leading to reduced vascular smooth muscle relaxation and compromised tissue perfusion.
- The ability of the vessel wall to prevent platelet adhesion and aggregation is diminished in atherosclerotic conditions.
- In patients with ischemic heart disease, endothelial dysfunction results in reduced coronary vessel dilation in response to physiological stimuli.
Conclusions:
- Endothelial dysfunction, particularly impaired nitric oxide (NO) formation, is a critical functional component of atherosclerosis.
- NO plays a vital role in maintaining vascular health by promoting vasodilation and potentially inhibiting atherosclerotic structural changes.
- Lipid-lowering therapies have demonstrated efficacy in reversing endothelial dysfunction in patients with atherosclerosis.
Abstract:
Atherosclerosis is characterized by hypertrophy of the vascular media, intimal thickening and lipid-containing plaques. Atherosclerosis is a progressive systemic vascular disease which leads to impaired tissue perfusion due to vascular obstruction. In advanced stages it is often complicated by thrombosis. Recent research demonstrates that atherosclerosis is also a functional disease. In atherosclerosis and hypercholesterolemia, normal vasodilatation is impaired due to endothelial dysfunction. In addition, the ability of the vessel wall to reject adhering and aggregating platelets is deteriorated. Endothelial dysfunction in atherosclerosis is characterized by impaired formation of nitric oxide (NO), formerly known as endothelium-derived relaxing factor (EDRF). NO is continuously formed in the vascular endothelium and promotes tissue perfusion by relaxation of vascular smooth muscle. Endogenously formed NO may also protect against foam cell formation and media hypertrophy, i.e. against the structural component of atherosclerosis. In patients with ischaemic heart disease, the endothelial dysfunction leads to decreased ability to dilate the coronary vessels in response to several forms of physiological stimuli. Endothelial dysfunction in atherosclerosis is reversed by lipid-lowering therapeutic interventions.